Literature DB >> 26420723

Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Ayesha Khalid, Joy Wolfram, Ilaria Ferrari, Chaofeng Mu, Junhua Mai, Zhizhou Yang, Yuliang Zhao, Mauro Ferrari, Xiaojing Ma, Haifa Shen1.   

Abstract

A variety of therapeutic strategies are currently under investigation to inhibit factors that promote tumor invasion, as metastasis is the most common cause of mortality for cancer patients. Notably, considerable emphasis has been placed on studying metastasis as a dynamic process that is highly dependent on the tumor microenvironment. In regards to breast cancer, chemokine C-C motif ligand 5 (CCL5), which is produced by tumor-associated stromal cells, has been established as an important contributor to metastatic disease. This review summarizes recent discoveries uncovering the role of this chemokine in breast cancer metastasis, including conditions that increase the generation of CCL5 and effects induced by this signaling pathway. In particular, CCL-5-mediated cancer cell migration and invasion are discussed in the context of intertwined feedback loops between breast cancer cells and stromal cells. Moreover, the potential use of CCL5 and its receptor chemokine C-C motif receptor 5 (CCR5) as targets for preventing breast cancer metastasis is also reviewed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26420723      PMCID: PMC4968951          DOI: 10.2174/138955751513150923094709

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  95 in total

1.  Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells.

Authors:  Suman Sengupta; Samir Jana; Subir Biswas; Palash Kumar Mandal; Arindam Bhattacharyya
Journal:  Clin Exp Metastasis       Date:  2013-07-06       Impact factor: 5.150

2.  Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.

Authors:  Sensen Lin; Shuying Wan; Li Sun; Jialiang Hu; Dongdong Fang; Renping Zhao; Shengtao Yuan; Luyong Zhang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

3.  Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12.

Authors:  T A Donlon; A M Krensky; M R Wallace; F S Collins; M Lovett; C Clayberger
Journal:  Genomics       Date:  1990-03       Impact factor: 5.736

4.  CCR5 antagonist blocks metastasis of basal breast cancer cells.

Authors:  Marco Velasco-Velázquez; Xuanmao Jiao; Marisol De La Fuente; Timothy G Pestell; Adam Ertel; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2012-05-25       Impact factor: 12.701

Review 5.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

6.  Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion.

Authors:  Georg Sauer; Nicole Schneiderhan-Marra; Cornelia Kazmaier; Kathrin Hutzel; Karin Koretz; Rainer Muche; Rolf Kreienberg; Thomas Joos; Helmut Deissler
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

7.  A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells.

Authors:  Yan Zhang; Dandan Lv; Ha-Jeong Kim; Robert A Kurt; Wen Bu; Yi Li; Xiaojing Ma
Journal:  Cell Res       Date:  2012-12-25       Impact factor: 25.617

8.  Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases.

Authors:  Muthulekha Swamydas; Krista Ricci; Stephen L Rego; Didier Dréau
Journal:  Cell Adh Migr       Date:  2013-05-24       Impact factor: 3.405

9.  Slug/β-catenin-dependent proinflammatory phenotype in hypoxic breast cancer stem cells.

Authors:  Gianluca Storci; Sara Bertoni; Sabrina De Carolis; Alessio Papi; Marina Nati; Claudio Ceccarelli; Chiara Pirazzini; Paolo Garagnani; Alberto Ferrarini; Genny Buson; Massimo Delledonne; Michelangelo Fiorentino; Elisa Capizzi; Elisa Gruppioni; Mario Taffurelli; Donatella Santini; Claudio Franceschi; Giuseppe Bandini; Francesca Bonifazi; Massimiliano Bonafé
Journal:  Am J Pathol       Date:  2013-09-12       Impact factor: 4.307

10.  Mesenchymal precursor cells in the blood of normal individuals.

Authors:  N J Zvaifler; L Marinova-Mutafchieva; G Adams; C J Edwards; J Moss; J A Burger; R N Maini
Journal:  Arthritis Res       Date:  2000-08-31
View more
  22 in total

Review 1.  Adipocyte and lipid metabolism in cancer drug resistance.

Authors:  Yihai Cao
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

2.  Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells.

Authors:  Jie Zi; Shushu Yuan; Jianlin Qiao; Kai Zhao; Linyan Xu; Kunming Qi; Kailin Xu; Lingyu Zeng
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

3.  Host CLIC4 expression in the tumor microenvironment is essential for breast cancer metastatic competence.

Authors:  Vanesa C Sanchez; Howard H Yang; Alayna Craig-Lucas; Wendy Dubois; Brandi L Carofino; Justin Lack; Jennifer E Dwyer; R Mark Simpson; Christophe Cataisson; Max P Lee; Ji Luo; Kent W Hunter; Stuart H Yuspa
Journal:  PLoS Genet       Date:  2022-06-21       Impact factor: 6.020

Review 4.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

5.  CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.

Authors:  Santosh Kumar Singh; Manoj K Mishra; Isam-Eldin A Eltoum; Sejong Bae; James W Lillard; Rajesh Singh
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.996

6.  CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.

Authors:  Asim Pervaiz; Michael Zepp; Saqib Mahmood; Doaa Mohamed Ali; Martin R Berger; Hassan Adwan
Journal:  Cell Oncol (Dordr)       Date:  2018-11-19       Impact factor: 7.051

7.  CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.

Authors:  Darrin Gao; Lisa H Cazares; Eleanor N Fish
Journal:  BMC Cancer       Date:  2017-12-08       Impact factor: 4.430

Review 8.  Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention.

Authors:  Manuel Picon-Ruiz; Cynthia Morata-Tarifa; Janeiro J Valle-Goffin; Eitan R Friedman; Joyce M Slingerland
Journal:  CA Cancer J Clin       Date:  2017-08-01       Impact factor: 508.702

Review 9.  Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.

Authors:  Jing Jin; Qijie Zhao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

10.  Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).

Authors:  Sreelatha K Hemalatha; Satheesh Kumar Sengodan; Revathy Nadhan; Jithin Dev; Reshma R Sushama; Veena Somasundaram; Ratheeshkumar Thankappan; Arathi Rajan; Neetha Rajan Latha; Geetu Rose Varghese; Arun Peter Mathew; Thara Somanathan; Priya Srinivas
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.